International journal of antimicrobial agents · 2025
Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016-2023.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jan Hao-En, Wang Jiun-Ling, Lee Nan-Yao, Hsueh Shun-Chung, Huang Yu-Tsung, Ko Wen-Chien, Hsueh Po-Ren
Аннотация
OBJECTIVE: The aim of this study is to investigate the trends in ceftazidime-avibactam (CZA) resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp., and Serratia marcescens globally using the database from Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016-2023.
METHODS: A total of 18,908 isolates (4,231 C. freundii, 4658 M. morganii, 3,570 Providencia spp., and 6449 S. marcescens) from five continents were analysed. Antimicrobial susceptibility testing of these isolates was conducted using the broth microdilution method.
RESULTS: The CZA resistance rate was the highest in Providencia spp. (8.8%), followed by C. freundii (3.4%), S. marcescens (1.5%), and M. morganii (0.6%). An increasing resistance trend was noted in C. freundii (R² = 0.817) and S. marcescens (R² = 0.995) during the study period. The resistance rate in Providencia spp. peaked in 2020-2021 (R² = 0.610), while that in M. morganii remained sporadically low. Regionally, the biannual resistant rate of C. freundii rose from 6.7% to 13.0% in Asia, 0% to 7.8% in Latin America, and 0% to 7.0% in East Asia (2016-2017 vs. 2022-2023). Furthermore, among carbapenem-resistant isolates, CZA resistance was noted in 91.1% of Providencia spp., 78.8% of C. freundii, 34.9% of S. marcescens, and 60% of M. morganii. The predominant carbapenemase gene was blaNDM in Providencia spp. (82.6%), M. morganii (69.2%), and C. freundii (42.0%), and blaKPC in S. marcescens (45.3%) among carbapenemase-producing isolates.
CONCLUSIONS: CZA resistance is emerging across diverse Enterobacterales species, and exhibits geographic and temporal variability, and warrants continued global surveillance.
METHODS: A total of 18,908 isolates (4,231 C. freundii, 4658 M. morganii, 3,570 Providencia spp., and 6449 S. marcescens) from five continents were analysed. Antimicrobial susceptibility testing of these isolates was conducted using the broth microdilution method.
RESULTS: The CZA resistance rate was the highest in Providencia spp. (8.8%), followed by C. freundii (3.4%), S. marcescens (1.5%), and M. morganii (0.6%). An increasing resistance trend was noted in C. freundii (R² = 0.817) and S. marcescens (R² = 0.995) during the study period. The resistance rate in Providencia spp. peaked in 2020-2021 (R² = 0.610), while that in M. morganii remained sporadically low. Regionally, the biannual resistant rate of C. freundii rose from 6.7% to 13.0% in Asia, 0% to 7.8% in Latin America, and 0% to 7.0% in East Asia (2016-2017 vs. 2022-2023). Furthermore, among carbapenem-resistant isolates, CZA resistance was noted in 91.1% of Providencia spp., 78.8% of C. freundii, 34.9% of S. marcescens, and 60% of M. morganii. The predominant carbapenemase gene was blaNDM in Providencia spp. (82.6%), M. morganii (69.2%), and C. freundii (42.0%), and blaKPC in S. marcescens (45.3%) among carbapenemase-producing isolates.
CONCLUSIONS: CZA resistance is emerging across diverse Enterobacterales species, and exhibits geographic and temporal variability, and warrants continued global surveillance.